Format

Send to

Choose Destination
Curr Gastroenterol Rep. 2005 Oct;7(5):389-95.

Chemoprophylaxis of colon cancer.

Author information

1
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA. breddy@rci.rutgers.edu

Abstract

There is convincing evidence that chemoprevention has the potential to be a major component of colorectal cancer control. Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents. However, several of these chemopreventive agents induce side effects at effective high dose levels. Low doses of atorvastatin and aspirin, or atorvastatin and celecoxib, or piroxicam and difluoromethylornithine administered in combination are more effective in inhibiting chemically induced colon adenocarcinomas in male F 344 rats than are high doses of these agents given individually.

PMID:
16168238
DOI:
10.1007/s11894-005-0009-x
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center